The Niche
More shots with mesenchymal stem cells
Yesterday, I reported on the failure of two late stage trials exploring mesenchymal stem cells to quell the potentally fatal immune response in graft versus host disease. Those trials were led by Osiris, a company in Maryland, which still hopes to look through its data and ongoing trials for signs of efficacy. See Stem-cell drug fails crucial trials